These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 26951185)

  • 1. Local excision of low rectal cancer treated by chemoradiotherapy: is it safe for all patients with suspicion of complete tumor response?
    Debove C; Guedj N; Tribillon E; Maggiori L; Zappa M; Panis Y
    Int J Colorectal Dis; 2016 Apr; 31(4):853-60. PubMed ID: 26951185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Local excision after neoadjuvant chemoradiotherapy for mid and low rectal cancer: a multicentric French study from the GRECCAR group.
    Calmels M; Labiad C; Lelong B; Lefevre JH; Tuech JJ; Benoist S; Mège D; Denost Q; Panis Y
    Colorectal Dis; 2023 Oct; 25(10):1973-1980. PubMed ID: 37679892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncologic Safety of Local Excision Compared With Total Mesorectal Excision for ypT0-T1 Rectal Cancer: A Propensity Score Analysis.
    Jung SM; Yu CS; Park IJ; Kim TW; Kim JH; Yoon YS; Lim SB; Kim JC
    Medicine (Baltimore); 2016 May; 95(20):e3718. PubMed ID: 27196490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Local excision for ypT2 rectal cancer following preoperative chemoradiation therapy: it should not be justified.
    Yang KM; Lim SB; Lee JL; Kim CW; Yoon YS; Park IJ; Yu CS; Kim JC
    Int J Colorectal Dis; 2018 Apr; 33(4):487-491. PubMed ID: 29468352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is it time to rethink the rule of total mesorectal excision? A prospective radiological and pathological study in 49 consecutive patients with mid-rectal cancer.
    Guedj N; Zappa M; Maggiori L; Bertin C; Hennequin C; Panis Y
    Colorectal Dis; 2016 Sep; 18(9):O314-21. PubMed ID: 27381492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Local excision after neoadjuvant chemoradiotherapy versus total mesorectal excision: a case-matched study in 110 selected high-risk patients with rectal cancer.
    Calmels M; Collard MK; Cazelles A; Frontali A; Maggiori L; Panis Y
    Colorectal Dis; 2020 Dec; 22(12):1999-2007. PubMed ID: 32813899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Outcome of Rectal Cancer With Clinically (EUS/MRI) Metastatic Mesorectal Lymph Nodes Treated by Neoadjuvant Chemoradiation: Role of Organ Preservation Strategies in Relation to Pathologic Response.
    Belluco C; Forlin M; Olivieri M; Cannizzaro R; Canzonieri V; Buonadonna A; Bidoli E; Matrone F; Bertola G; De Paoli A
    Ann Surg Oncol; 2016 Dec; 23(13):4302-4309. PubMed ID: 27489059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Total Mesorectal Excision Versus Local Excision After Favorable Response to Preoperative Chemoradiotherapy in "Early" Clinical T3 Rectal Cancer: A Propensity Score Analysis.
    Shin YS; Yu CS; Park JH; Kim JC; Lim SB; Park IJ; Kim TW; Hong YS; Kim KP; Yoon SM; Joo JH; Kim JH
    Int J Radiat Oncol Biol Phys; 2017 Sep; 99(1):136-144. PubMed ID: 28816139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Lymph node metastases in ypT1/2 rectal cancer after neoadjuvant chemoradiotherapy : The Achilles heel of organ-preserving operative procedures?].
    Sprenger T; Rothe H; Beissbarth T; Conradi LC; Kauffels A; Homayounfar K; Behnes CL; Rödel C; Liersch T; Ghadimi M
    Chirurg; 2016 Jul; 87(7):593-601. PubMed ID: 27106241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Total Mesorectal Excision Versus Local Excision After Preoperative Chemoradiotherapy in Rectal Cancer With Lymph Node Metastasis: A Propensity Score-Matched Analysis.
    Shin YS; Park JH; Yoon SM; Kim JC; Yu CS; Lim SB; Park IJ; Kim TW; Hong YS; Kim KP; Choi EK; Ahn SD; Lee SW; Kim JH
    Int J Radiat Oncol Biol Phys; 2018 Jul; 101(3):630-639. PubMed ID: 29678529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Local excision in mid-to-low rectal cancer patients who revealed clinically total or near-total regression after preoperative chemoradiotherapy; a proposed trial.
    Lee JL; Lim SB; Yu CS; Park IJ; Yoon YS; Kim CW; Park SH; Lee JS; Hong YS; Kim SY; Kim JE; Kim JH; Park JH; Kim J; Han M
    BMC Cancer; 2019 Apr; 19(1):404. PubMed ID: 31035949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-inferiority multicenter prospective randomized controlled study of rectal cancer T
    Serra-Aracil X; Pericay C; Golda T; Mora L; Targarona E; Delgado S; Reina A; Vallribera F; Enriquez-Navascues JM; Serra-Pla S; Garcia-Pacheco JC;
    Int J Colorectal Dis; 2018 Feb; 33(2):241-249. PubMed ID: 29234923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant chemoradiation and local excision for T2-3 rectal cancer.
    Borschitz T; Wachtlin D; Möhler M; Schmidberger H; Junginger T
    Ann Surg Oncol; 2008 Mar; 15(3):712-20. PubMed ID: 18163173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Individualizing surgical treatment based on tumour response following neoadjuvant therapy in T4 primary rectal cancer.
    Denost Q; Kontovounisios C; Rasheed S; Chevalier R; Brasio R; Capdepont M; Rullier E; Tekkis PP
    Eur J Surg Oncol; 2017 Jan; 43(1):92-99. PubMed ID: 27717529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathological characteristics predict lymph node metastases in ypT0-2 rectal cancer after chemoradiotherapy.
    Bosch SL; Vermeer TA; West NP; Swellengrebel HA; Marijnen CA; Cats A; Verhoef C; van Lijnschoten I; de Wilt JH; Rutten HJ; Nagtegaal ID
    Histopathology; 2016 Nov; 69(5):839-848. PubMed ID: 27270756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can clinicopathological parameters predict for lymph node metastases in ypT0-2 rectal carcinoma? Results of the CAO/ARO/AIO-94 and CAO/ARO/AIO-04 phase 3 trials.
    von den Grün JM; Hartmann A; Fietkau R; Ghadimi M; Liersch T; Hohenberger W; Weitz J; Sauer R; Wittekind C; Ströbel P; Rödel C; Fokas E;
    Radiother Oncol; 2018 Sep; 128(3):557-563. PubMed ID: 29929861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncologic outcome after preoperative chemoradiotherapy in patients with pathologic T0 (ypT0) rectal cancer.
    Jang TY; Yu CS; Yoon YS; Lim SB; Hong SM; Kim TW; Kim JH; Kim JC
    Dis Colon Rectum; 2012 Oct; 55(10):1024-31. PubMed ID: 22965400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer.
    Chau I; Brown G; Cunningham D; Tait D; Wotherspoon A; Norman AR; Tebbutt N; Hill M; Ross PJ; Massey A; Oates J
    J Clin Oncol; 2006 Feb; 24(4):668-74. PubMed ID: 16446339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short- and long-term outcomes in ypT2 rectal cancer patients after neoadjuvant therapy and local excision: a multicentre observational study.
    Peltrini R; Castiglioni S; Imperatore N; Ortenzi M; Rega D; Romeo V; Caracino V; Liberatore E; Basti M; Santoro E; Bracale U; Delrio P; Mucilli F; Guerrieri M; Corcione F
    Tech Coloproctol; 2023 Jan; 27(1):53-61. PubMed ID: 36239872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective lateral pelvic lymph node dissection in patients with advanced low rectal cancer treated with preoperative chemoradiotherapy based on pretreatment imaging.
    Akiyoshi T; Ueno M; Matsueda K; Konishi T; Fujimoto Y; Nagayama S; Fukunaga Y; Unno T; Kano A; Kuroyanagi H; Oya M; Yamaguchi T; Watanabe T; Muto T
    Ann Surg Oncol; 2014 Jan; 21(1):189-96. PubMed ID: 23963871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.